VTE Prevention Following Total Hip and Knee Arthroplasty
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Consented patients undergoing elective total hip and total knee arthroplasty will be
randomized to receive either aspirin alone or aspirin and rivaroxaban for prevention of
venous thromboembolism.
Phase:
Phase 3
Details
Lead Sponsor:
Sudeep Shivakumar
Collaborators:
Canadian Institutes of Health Research (CIHR) Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network CanVECTOR Nova Scotia Health Authority